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Abstract Coronary artery disease is the result of athero-
sclerotic changes to the coronary arterial wall, compris-
ing endothelial dysfunction, vascular inflammation and
deposition of lipid-rich macrophage foam cells. Certain
high-risk atherosclerotic plaques are vulnerable to dis-
ruption, leading to rupture, thrombosis and the clinical
sequelae of acute coronary syndrome. Though
recognised as the gold standard for evaluating the pres-
ence, distribution and severity of atherosclerotic lesions,
invasive coronary angiography is incapable of identify-
ing non-stenotic, vulnerable plaques that are responsible
for adverse cardiovascular events. The recognition of
such limitations has impelled the development of
intracoronary imaging technologies, including intravas-
cular ultrasound, optical coherence tomography and
near-infrared spectroscopy, which enable the detailed
evaluation of the coronary wall and atherosclerotic
plaques in clinical practice. This review discusses the
present status of invasive imaging technologies; summa-
rises up-to-date, evidence-based clinical guidelines; and
addresses questions that remain unanswered with regard
to the future of intracoronary plaque imaging.
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Introduction
Despite significant advancements in pharmacological and in-
terventional management, coronary artery disease (CAD) re-
mains the leading cause of morbidity and mortality worldwide
[1, 2]. The first clinical manifestation of CAD is often acute
coronary syndrome (ACS), comprising ST-elevation and non-
ST-elevation acute myocardial infarction (MI) and unstable
angina pectoris. CAD comprises a continuum of pathophysi-
ological changes to the intima and media of the coronary
arterial wall, characterised by endothelial dysfunction; vascu-
lar inflammation; accumulation of lipid, calcium and cellular
debris; and in certain plaques, coronary artery stenosis. Long-
established as the gold standard to evaluate the presence, lo-
cation and extent of stenosis associated with CAD, invasive
coronary angiography provides a two-dimensional represen-
tation of the coronary lumen but is incapable of visualising the
composition of the atherosclerotic plaque [3]. Approximately
two thirds of acute coronary events occur due to the rupture of
lesions with non-critical (≤50 %) stenosis on angiography and
are characterised by specific histological features conferring
vulnerability [4–6].
Impelled by the inherent limitations of coronary angiogra-
phy, complementary imaging modalities have emerged, capa-
ble of visualising the components of the arterial wall and
characterising coronary plaques. Intravascular ultrasound
(IVUS), optical coherence tomography (OCT) and near-
infrared spectroscopy (NIRS) are techniques capable of ro-
bust, qualitative and quantitative evaluation of the coronary
artery wall, and plaques contained within [7–9]. Emerging
clinical evidence suggests that intracoronary imaging is a safe
and effective adjunct to angiography, both as a research tool
and in clinical practice, providing superior diagnostic preci-
sion regarding plaque architecture, composition and severity
and enabling incremental risk stratification. However, despite
accumulating evidence, guidelines regarding the use of
intracoronary imaging for the detection of vulnerable coronary
plaques remain limited [10, 11].
The purpose of this review is to provide a critical overview
of the applications of in vivo intracoronary imaging tech-
niques, in the identification of high-risk, vulnerable athero-
sclerotic plaques. This review will discuss the available imag-
ing technologies, consider their relative benefits and limita-
tions and explore how the invasive imaging of high-risk, vul-
nerable plaques may advance in the future.
The Vulnerable Atherosclerotic Plaque
The concept of the high-risk or vulnerable plaque emerged
from landmark, longitudinal studies of patients with ST-
elevation MI. Analysis of serial and pre- and post-infarct an-
giography demonstrated contrary to popular belief that most
infarctions were not caused by severely stenotic lesions [5,
12]. The plaques attributed to causing infarction were moder-
ately sized at baseline. This is explained by expansive remod-
elling in the arterial wall; the lumen remains uncompromised
until the plaque achieves a critical volume. Thus, the degree of
stenosis is not the primary determinant of plaque rupture.
A post-mortem, histopathological study examined the
hearts of 113 men, 41 of which had thrombosis secondary to
vulnerable plaque rupture. Of these, 95 % of lesions had thin
fibrous caps, with macrophage infiltrate overlying a lipid-rich
pool [6]. The thin-cap fibroatheroma (TCFA) represents a
specific morphology of vulnerable plaque, characterised by a
thin fibrous layer overlying a large core of lipid-rich necrotic
debris and associated with expansive arterial remodelling [13,
14]. TCFA is most frequently observed in the proximal coro-
nary vasculature. Key characteristics conferring vulnerability
to rupture include the presence of (i) a thin fibrous cap
(<65 μm); (ii) a large, lipid-enriched, necrotic core (>40 %
total plaque volume); (iii) localised macrophage infiltration
and inflammation; (iv) vascular remodelling; (v) densely cal-
cified areas (>10 %); and (vi) large plaque volume [15].
Inflammation secondary to shoulder macrophage activation,
endothelial denudation, superficial thrombocyte aggregation
and haemodynamically significant stenosis (>90 %) further
predispose to rupture and subsequent atherothrombosis [16].
The majority of vulnerable plaques remain clinically silent
until the development of acute MI, emphasising the impor-
tance of early identification, enabling prognostic stratification
and optimisation of management (e.g. risk factor modifica-
tion; secondary preventative pharmacotherapy).
IVUS
IVUS Technology Greyscale IVUS uses the amplitude of
reflected ultrasound waves to generate an image [17–19].
Many successful applications of IVUS in research have great-
ly advanced the understanding of the pathophysiology and
natural history of coronary atherosclerosis, such as providing
the first in vivo evidence of expansive arterial remodelling
[20]. IVUS permits detailed evaluation of the coronary artery
lumen, wall and plaque area and enables both qualitative and
quantitative and pre- and post-intervention assessment of le-
sion morphology, to a depth of 5–10 mm, with an axial spatial
resolution of 100–200 μm at frequencies ranging from 20 to
45 MHz. The IVUS catheter is mounted to an automated pull-
back device, which withdraws the catheter at a pre-set speed
(e.g. 0.5 mm s−1), enabling the acquisition of a cylinder, rep-
resentative of a length of an artery.
The highly reproducible nature of vessel and plaque mea-
surements using IVUS has been robustly validated [21]. The
greyscale image provided by IVUS permits classification of
multiple tissues: (i) soft, with echogenicity less than nearby
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adventitia; (ii) calcified, with echogenicity greater than
nearby adventitia; (iii) fibrous, with intermediate
echogenicity; and (iv) mixed, with several visible acoustic
signals [22, 23]. However, IVUS lacks sensitivity in the
identification of lipid-rich plaque (approximately two
thirds of all plaques) and has suboptimal spatial resolution
to permit a detailed analysis of plaque characteristics, such
as visualisation or measurement of fibrous cap thickness
(Fig. 1a) [17, 24]. In addition, IVUS cannot reliably iden-
tify a thrombus [18]. High-frequency transducers
(>40 MHz) yield increased resolution, with improved
plaque characterisation, at the cost of greater artefact due
to reflection of ultrasound from the blood and reduced
depth of penetration. Although this may cause confusion
Fig. 1 Examples of intracoronary imaging modalities. a (VH-)IVUS.
The coronary angiogram shows the left anterior descending artery
(RAO cranial), demonstrating minimal stenosis, but multiple vulnerable
plaques are visualised on IVUS. Cross-sectional images demonstrate
calcified TCFA (blue line, IVUS1 and VH1) and non-calcified TCFA
(red line, IVUS2 and VH2). Keys to VH-IVUS: dark green fibrous
tissue, light green fibro-fatty tissue, red necrotic core, white dense
calcium. b OCT. Several examples of features associated with plaque
vulnerability are presented, including: OCT1 TCFA (arrow indicates
thin fibrous cap), OCT2 coronary arterial calcification (arrows indicate
well-demarcated calcification),OCT3 necrotic core (arrows indicate lipid
pool/necrotic core), OCT4 presence of cholesterol microcrystal (arrow
indicates well-demarcated crystal structure), OCT5 microchannels
(arrows indicate two separate channels) associated with a non-
obstructive lesion and OCT6 (white arrows indicate low-attenuation
white thrombus; red arrows indicate highly fibrous plaque). Diag
diagonal artery, IVUS intravascular ultrasound, LAD left anterior
descending artery, LCx left circumflex artery, LMS left main stem, OCT
optical coherence tomography, OM obtuse marginal artery, prob
probability, RAO right anterior oblique view, TCFA thin-cap
fibroatheroma, VH virtual histology. Asterisk indicates guidewire
artefact; dagger indicates seam line artefact
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in interpreting margins between structures (e.g. the lumen-
tissue border), this may be resolved by catheter-guided
saline injection [25].
Integrated Backscatter IVUS and Virtual Histology IVUS
Technology Qualitative assessment of plaque morphology
using greyscale IVUS requires significant post-processing;
the development of plaque characterisation algorithms, such
as integrated backscatter IVUS (IB-IVUS) and virtual histol-
ogy IVUS (VH-IVUS), reduces operator-dependent image in-
terpretation. These techniques augment greyscale IVUS im-
ages with a colour map of the plaque architecture, stratified by
a tissue type. IB-IVUS uses time domain information extract-
ed directly from the radio-frequency signal to characterise
plaque constituents, with high sensitivity and specificity [26,
27]. VH-IVUS is performed using either a 20-MHz phased
array or a 45-MHz rotational catheter and uses spectral anal-
ysis of the frequency and amplitude of ultrasound signals
reflected by tissues to characterise plaque components, using
an algorithm derived from known tissue types, to detect fi-
brous tissue (FT, dark green), fibro-fatty tissue (FFT, light
green), necrotic core (NC, red) and dense calcium (DC, white;
Fig. 1a) [28–31].
The sensitivity and specificity of VH-IVUS is broadly sim-
ilar to that of IB-IVUS; the degree of concordance between
VH-IVUS and in vitro histopathology (following atherecto-
my) was 87.1–96.5%, dependent on tissue [32–34]. However,
discrepant results exist with regard to the identification of NC;
several studies demonstrate poor associations between VH-
IVUS and histological analysis [35, 36]. This is partly due to
the fact that the initial VH-IVUS spectral classification did not
differentiate between necrotic and calcified areas, combining
the two into calcified-necrotic regions [37].
IVUS, IB-IVUS, VH-IVUS and Vulnerable Plaques
Definitions The definition of TCFA on IVUS should reflect
the histopathological characteristics of TCFA but must respect
the limitations of the imaging modality. As such, given the
limited resolution of IVUS, the absence of visible fibrous
tissue overlying a lipid core implies a cap thickness of
≤100–200 μm. As such, the majority of IVUS studies adopt
a simplified definition of TCFA, as a focal necrotic core-rich
lesion, without evidence overlying fibrous tissue [38].
IVUS and ACS The multi-centre, PROSPECT (Providing
Regional Observations to Study Predictors of Events in the
Coronary Tree) cohort study recruited n=697 patients with
ACS undergoing percutaneous coronary intervention (PCI)
to undergo three-vessel greyscale and VH-IVUS [39]. The
primary endpoint was a composite of MI, rehospitalisation,
cardiac arrest and cardiac-related mortality. A total of 596
TCFA cases were visualised in 313 patients. After a median
of 3.4-year follow-up, the rate of the primary endpoint was
20.4 %; events during follow-up were attributed to the culprit
lesion in only 12.9 %. Most of the non-culprit lesions causa-
tive of follow-up events were angiographically mild at recruit-
ment (mean ± standard deviation diameter stenosis 32.3
± 20.6 %). Multivariate analysis demonstrated that non-
culprit lesions associated with events were more likely to be
associated with (i) plaque burden of ≥70 % (hazard ratio (HR)
5.03, 95 % confidence interval (CI) 2.51–10.11; p<0.001),
(ii) minimal luminal area of ≤4.0 mm2 (HR 3.21, 95 % CI
1.61–6.42; p=0.001) or (iii) underlying IVUS-TCFA (HR
3.35, 95 % CI 1.77–6.36; p<0.001). However, 48 % of the
lesions causing events during follow-up were not imaged at
baseline in PROSPECT; IVUS imaging was limited to the
proximal and middle portions of the arteries, where the vessel
diameter was sufficient to accommodate the IVUS catheter.
Crucially, this study suggests that adverse cardiac events have
a propensity to occur, with reasonable frequency, at the site of
non-culprit lesions.
The VIVA (VH-IVUS and Vulnerable Atherosclerosis)
study also prospectively evaluated the association between
TCFA and adverse coronary events in n=170 patients, with
stable angina and ACS, undergoing PCI [28]. All patients
underwent a three-vessel VH-IVUS pre- and post-PCI. The
primary endpoint consisted of myocardial infarction, un-
planned revascularisation or death. At a median of 1.75-year
follow-up, the primary endpoint was attributed to 19 lesions (6
culprit and 13 non-culprit) in 16 patients. The same non-
culprit factors identified in PROSPECT also associated with
the primary endpoint: plaque burden (HR 8.13, 95% CI 1.63–
40.56; p=0.011), luminal area (HR 2.91, 95 % CI 1.07–7.91;
p=0.036) and VH-TCFA presence (HR 7.53, 95 % CI 1.12–
50.55; p=0.038). This study demonstrates the prognostic sig-
nificance of IVUS in the identification of patients at high risk
of experiencing adverse cardiovascular outcomes.
Recently, the ATHEROREMO-IVUS (European
Collaborative Project on Inflammation and Vascular Wall
Remodelling in Atherosclerosis-Intravascular Ultrasound)
study assessed the value of IVUS in patients with CAD
[40••]. A total of n=581 patients undergoing PCI for stable
angina (n=263) and ACS (n=318) underwent VH-IVUS of a
non-culprit artery. The primary endpoint comprised a compos-
ite of ACS, unplanned revascularisation or death. Of 724 le-
sions identified by VH-IVUS, 271 (37 %) satisfied criteria for
VH-TCFA. At 1-year follow-up, 56 patients had at least one
event, 11 had a culprit lesion-related event (which were
discounted), 27 had a definite non-culprit lesion-related event
and the remaining 18 had an indeterminate event (an event
that could not be judged to be either culprit or non-culprit
lesion related). The presence of VH-TCFAwas independently
associated with the composite endpoint (adjusted HR 1.98,
95 % CI 1.09–3.60; p = 0.026), as was plaque burden
28 Page 4 of 12 Curr Cardiol Rep (2016) 18: 28
(adjusted HR 2.90, 95%CI 1.60–5.25; p<0.001). In addition,
the ATHEROREMO-IVUS was the first study to demonstrate
that the presence of VH-TCFA in non-culprit vessels is asso-
ciated with the hard endpoints of death and ACS at 1 year, not
just unplanned rehospitalisation or revascularisation. This
study also demonstrated that it may not be necessary to image
all three coronary arteries to gain information about the pan-
coronary vulnerability of the patient.
Together, these landmark studies demonstrate the prognos-
tic potential of VH-IVUS; illustrating how information ac-
quired using this imaging modality regarding plaque burden,
minimal luminal area and the presence of TCFA, could be
used to incrementally stratify risk in patients with proven
CAD.
IVUS and Calcified Plaques Recently, Amano et al. per-
formed a cross-sectional study to evaluate the association be-
tween angiographic plaque calcification and vulnerability via
the identification of TCFA using VH-IVUS in n=140 consec-
utive patients with ACS [41]. Patients were divided into four
groups according to degree of calcification: (i) none (no cal-
cium detected in any lesion; n=37), spotty (circumferential
calcium deposits <90°; n=65), intermediate (calcium deposits
≥90° but <180°; n= 37) and extensive (calcium deposits
≥180°; n=16). The mean number of VH-TCFA in the spotty
calcification group was significantly greater than that in the no
calcification, intermediate and extensive groups (0.66±0.71
vs. 0.22±0.42, p<0.01; 0.32±0.48, p<0.05; and 0.13±0.34,
p<0.01, respectively). In addition, the group with spotty cal-
cification had a significantly greater necrotic core compared to
that with angiographic calcification (p<0.05). The presence
of angiographic and VH-IVUS calcification correlated strong-
ly (p<0.05). These data suggest that calcified lesions are high-
ly vulnerable; those with spotty or intermediate calcification
onVH-IVUS, without angiographic calcification, appear to be
more vulnerable than those with angiographic calcification.
However, care should be taken with these results, due to the
potential issues with the misclassification of necrotic core and
dense calcium on the VH-IVUS algorithm.
OCT
OCT Technology OCT, which uses the reflection of near-
infrared light to generate an image, offers unparalleled spatial
resolution (<10 μm axial; 20–40 μm lateral) and is a core
intravascular imaging modality in clinical practice [42, 43].
OCT uses a low-coherence, near-infrared light source (centre
wavelength, λo=1.3 μm) which is directed at and reflected
from the vessel wall. The complex principles underlying im-
age generation have been previously described [44]. The OCT
catheter contains an optical fibre, which rotates to acquire an
image, and is mounted on an automated pullback device,
which images the artery in a helical fashion (Fig. 1b). OCT
enables high-resolution imaging at the cost of significant ar-
tefact due to blood cells, which scatter light and attenuate the
image. Therefore, a bloodless field is required for optimal
image acquisition.
Two main methods of OCT are in existence: first-
generation time domain OCT (TD-OCT), which has largely
been superseded by second-generation frequency domain
OCT (FD-OCT) [43]. TD-OCT generates an image by se-
quentially measuring isolated near-infrared optical reflections
at various depths, with the use of a moving reference mirror.
However, this technique is slow (e.g. with pullback speed 1–
5 mm s−1; image acquisition ≥45 s) and requires either prox-
imal balloon occlusion (potentially pro-arrhythmogenic) or
continuous flushing with iso-osmolar contrast to obtain
artefact-free images. Frequency domain OCT uses a near-
infrared source capable of generating λo=1.25–1.35 μm at a
single point, recording reflections at different depths without
movement of the reference mirror. Depth profiles, reconstruct-
ed using Fourier transformation, permit 10-fold faster acqui-
sition (e.g. with pullback speed 15–40 mm s−1; image acqui-
sition 3–5 s), without proximal occlusion and minimising con-
trast injection.
OCT enables high-resolution characterisation of the vascular
layers within a healthy artery and can identify morphological
changes to the vessel surface associated with high-risk, vulner-
able atherosclerotic plaques, including fibrous, lipid-rich and
calcified lesions, in addition to red and white thrombus, and
macrophages (Fig. 1b) [45, 46]. Potential disadvantages of
OCT include a limited depth of penetration (1–2.5 mm) partic-
ularly through lipid-rich lesions, the inability to image the ad-
ventitia to assess plaque burden, the requirement for a blood-free
field and common imaging artefacts [43, 44].
OCTand Vulnerable Plaques
Definitions As the axial resolution of OCT is much greater
than the diagnostic cut-off for the thin fibrous cap of TCFA,
OCT is well placed to identify these in vivo. However, an
ongoing debate exists with regard to the precise definition of
a TCFA on OCT imaging: there is significant discrepancy
between TCFA morphology on histological vs. OCT analysis
[47]. In a study of n=43 patients with ACS, Tanaka et al.
utilised OCT to characterise plaque rupture at the culprit site.
Using a cut-off of 70 μm, the authors demonstrated that 67 %
of ruptured plaques demonstrated a thin fibrous cap, in stark
comparison to the ≥95 % quoted in histopathological studies
[6, 48]. It has been hypothesised that this may be a conse-
quence of the shrinkage of pathological specimens; the true
thickness of a TCFA cap may be greater in vivo. Although
some studies advocate that the arc of the underlying lipid pool
in TCFA should subtend an angle of ≥90°, there is no
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consensus that this should be incorporated into the definition
of OCT-TCFA.
OCT-TCFA in ACS OCT has been utilised to accurately
detect and discriminate between various plaque compositions,
predicting peri-PCI complications [46]. A case-control study
comparing 26 patients with ST-elevation MI to 16 with stable
angina demonstrated that the ACS patients had greater inci-
dence of OCT-TCFA in the culprit lesion (85 vs. 13 %,
p<0.001), with a reduced fibrous cap wall diameter (57±12
vs. 180±65μm, p<0.001) [49]. This was replicated in similar
studies, comparing OCT-TCFA prevalence in ST-elevation vs.
non-ST-elevation ACS (78 vs. 49 %, respectively; p=0.008)
[50] and in unstable vs. stable angina pectoris (81 vs. 47 %,
respectively; p=0.002) [51]. In each study, the average cap
thickness was less for the group with greater disease severity,
i.e. average thickness in STEMI < NSTEMI < unstable angina
< stable angina, respectively [49–51].
In addition, OCT may be used to differentiate between
TCFA and eroded or calcified plaques [45]. The features as-
sociated with plaque erosion, such as luminal thrombus with
absent surface endothelium, have been correlated with sudden
cardiac death [52, 53]. While OCT may correctly identify an
irregular luminal surface, the resolution of OCT is inadequate
to visualise endothelium [44, 53]. The use of OCT to detect
plaque erosion may be particularly beneficial in ST-elevation
MI to guide thrombectomy [54].
OCT and Neoatherosclerosis OCT has permitted new in-
sights into the pathophysiology of neoatherosclerosis, in-
stent restenosis and thrombosis. Initially thought to be associ-
ated with the early period after bare-metal stent deployment,
evidence of in-stent restenosis has emerged both early and late
following insertion of bare-metal and drug-eluting stents and
can present as ACS [55, 56]. OCT imaging following stent
deployment demonstrates the transformation of the neointima
(which forms as a result of stent neovascularisation) to acquire
features of lipid-rich, vulnerable plaque: a process termed
neoatherosclerosis [57]. In one study, n=50 patients with in-
stent restenosis, and intimal hyperplasia >50 % of drug-
eluting stent area, underwent OCT, which demonstrated the
presence of TCFA in over half [57]. In a further study, serial
OCT observed that approximately one third of patients with
homogenous neointimal proliferation demonstrated progres-
sion to neoatherosclerosis [58]. As a result, patients with
neoatherosclerosis are more likely to develop adverse sequel-
ae, e.g. stent thrombosis and ACS, than those without [59, 60].
OCT in Vulnerable Plaque Monitoring The efficacy of
pharmacotherapeutic agents in stabilising vulnerable plaques
and preventing rupture has been evaluated using OCT.
Takarada et al. used serial OCT imaging to compare plaque
morphology in n=40 patients, allocated to receive either statin
therapy or no statin treatment, post-MI [61]. At 9 months, the
authors report increases in fibrous cap depth in both groups,
with a greater benefit observed in statin-treated patients (192
±41 vs. 25±8 μm, respectively; p<0.001). However, the sig-
nificance of these changes with regard to clinical outcome is
uncertain. A further, prospective trial, evaluating the effect of
statin pharmacotherapy on vulnerable plaque morphology in
n=42 patients with stable angina demonstrated a significant
increase in fibrous cap thickness in a statin-treated vs. dietary
modification group (52 ± 32 vs. 2 ± 22 μm, respectively;
p<0.001) [62]. No differences were reported in clinical out-
come at a median follow-up of 9 months; no patients experi-
enced MI or cardiac-related death, and target vessel
revascularisation was similar in both groups (15.4 vs. 18.7 %,
respectively; p=0.776). Nishio et al. randomised n=30 patients
with untreated dyslipidaemia and ≥1 TCFA on baseline OCT to
receive statin therapy with or without eicosapentaenoic acid,
observing that despite similar levels of low-density lipoprotein
at follow-up, patients that received eicosapentaenoic acid expe-
rienced greater increases in cap thickness vs. controls (54.8
± 27.9 vs. 23.5 ± 11.6 μm, respectively; p< 0.0001) [63].
However, while OCTcan provide evidence of positive morpho-
logical improvements to TCFA, further, longitudinal investiga-
tions, with adequate sample sizes, are required to establish if
these changes improve clinical outcomes.
NIRS
NIRS TechnologyNIRS is a recently developed imaging mo-
dality, first tested in vivo in humans in 2001, and is developed
for clinical applications over the past decade [64, 65]. NIRS
uses a catheter-mounted core of optical fibres to emit and
receive diffuse reflectance near-infrared light (λo = 0.8–
2.5 μm) [66, 67]. Similar to OCT, the NIRS catheter contains
an optical fibre which rotates (240 rotations min−1) to acquire
an image and is mounted on an automated pullback device.
The emitted wavelengths are absorbed in a specific pattern by
each component of an atherosclerotic plaque. The diffuse re-
flectance signals from the tissue are converted to spectra,
which undergo algorithmic transformation into a chemogram:
a map of the arterial wall, which displays signals suggestive of
lipid-core plaque (LCP) [68]. LCP is defined as a plaque
≥2 mm in length, with arterial circumference ≥60° [69]. The
x-axis represents the position of the catheter relative to the start
of the pullback; the y-axis indicates the degree of rotation [70,
71]. Red and yellow demonstrate low and high probability of
LCP presence, respectively [72, 73]. The chemogram un-
dergoes further processing to yield a summary, block
chemogram, providing an interpretation of results for each
2-mm segment of an artery. The same colours are used for
the chemogram, which are dependent on the probability of
LCP in a given 2-mm region of an artery: red (p<0.57),
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orange (0.57 ≤ p < 0.84), tan (0.84 ≤ p < 0.98) and yellow
(p≥ 0.98) [74]. Unlike the aforementioned imaging tech-
niques, NIRS penetrates effectively through calcium and
stents. It does not require post-processing nor a bloodless op-
erating field. However, that NIRS provides only composition-
al insight (i.e. the probability of a lipid-core plaque at a given
site) without any quantitative or morphological data (e.g. lu-
men size, plaque volume) is a limitation [75].
Algorithm Derivation and Validation The algorithm for lip-
id detection was calibrated using post-mortem coronary arter-
ies [71]. Gardner et al. performed NIRS within 212 segments
of a coronary artery (from 84 ex vivo hearts), followed by
histopathological analysis of sections taken at 2-mm intervals.
The first 33 hearts were used to develop the algorithm; the
remaining 51 were used in prospective, double-blind fashion
to evaluate NIRS in identifying LCP. The algorithm identified
LCP with a receiver-operator characteristic area of 0.80 (95 %
CI 0.76–0.85) and sensitivity and specificity of 49 and 90 %,
respectively [71]. The SPECTACL (SPECTroscopic
Assessment of Coronary Lipid) study was performed to vali-
date the NIRS algorithm in vivo in n=106 patients. This study
demonstrated the feasibility and safety of spectral data collec-
tion via NIRS, with reasonable sensitivity and specificity [67].
NIRS and Vulnerable Plaques
LCP, NIRS and ACS The ATHEROREMO-NIRS
(European Collaborative Project on Inflammation and
Vascular Wall Remodelling in Atherosclerosis-Near-Infrared
Spectroscopy) study was performed to assess the prognostic
value of NIRS [76••]. NIRS was performed in a non-culprit
coronary artery in n=203 patients undergoing PCI for stable
angina or ACS; LCP within the vessel was measured as the
maximal lipid-core burden index (LCBI). Patients were
followed up for a median duration of 1 year for a composite
endpoint of all-cause mortality, non-fatal ACS, stroke and
unplanned coronary revascularisation. Patients with LCBI
greater than the median value experienced a significantly
greater rate of the composite endpoint vs. patients with
LCBI less than the median value (16.7 vs. 4.0 %, respectively;
adjusted HR 4.04, 95 % CI 1.33–12.29; p=0.01).
The prospective, multi-centre COLOR (Chemometric
Observation of Lipid-Core Plaques of Interest in Native
Coronary Arteries Registry) registry was established to eval-
uate the association between the presence of LCP and peri-
procedural MI [74]. Sixty-two patients with stable pre-
procedural cardiac biomarkers underwent NIRS prior to PCI.
Peri-procedural MI (defined as a cardiac biomarker rise great-
er than or equal to three times the upper limit of normal)
occurred in 7 patients with large LCP (LCBI ≥500; n=14),
compared to 2 patients with lower LCP (n= 48) giving a
relative risk of 12 (95 % CI 3.3–48; p=0.0002), demonstrat-
ing a significant association between high LCP burden and
peri-procedural MI.
The recent prospective, multi-centre CANARY (Coronary
Assessment by Near-infrared of Atherosclerotic Rupture-prone
Yellow) study demonstrated that treatment with PCI reduced
LCP burden [77]. Patients experiencing peri-procedural MI
had greater LCBI vs. patients without MI (481.5 vs. 371.5;
p=0.05). In addition, the effectiveness of a distal protection
device in preventing peri-procedural MI was assessed in 31
lesions with LCBI ≥600. Patients were randomised to receive
PCI with distal protection (n=14) vs. PCI without distal protec-
tion (n=17). The use of distal protection device had no effect on
the rate of peri-procedural MI (p=0.69).
Comparing Established Imaging Techniques
Several studies have investigated the comparative accuracy of
different imaging modalities to detect vulnerable coronary
plaque. A recent study by Kini et al. compared IVUS, OCT
andNIRS in n=110 patients with established CAD, with regard
to the prediction of peri-procedural MI [78•]. In patients that
developed peri-procedural MI (n=10), OCT-derived minimum
fibrous cap thickness was significantly lower compared to those
that did not develop MI (55 vs. 90 μm, respectively; p<0.01).
Both IVUS-measured plaque burden (84± 9 vs. 77 ± 8 %;
p<0.01) and NIRS-measured LCBI (556 vs. 339, p<0.01)
were greater in the peri-procedural MI group. The authors per-
formed multivariate logistic regression, identifying OCT cap
thickness as the only predictor of peri-procedural MI (odds ratio
(OR) 0.91, 95 % CI 0.81–0.98; p=0.04). When removed from
the model, the IVUS- and NIRS-derived measures became sig-
nificant predictors. Thus, OCT-based fibrous cap thickness, sug-
gesting significant plaque vulnerability, is the most significant
predictor of peri-procedural MI.
Numerous studies demonstrate that, while the absolute,
in vivo diagnostic sensitivity of each imaging technique is
favourable, the synergistic use of multiple imaging methodol-
ogies may be advantageous. Indeed, to this end, active pre-
clinical and clinical research is ongoing to combine imaging
modalities.
Hybridisation of IVUS and OCT Many investigators have
speculated that the fusion of IVUS and OCT would prove an
optimal imaging strategy. The enhanced resolution of OCT
would enable the precise assessment of luminal morphology
(i.e. identification of cap thickness, thrombus and plaque ero-
sion), whereas the increased penetration of IVUSwould allow
the evaluation of plaque burden, architecture and remodelling.
The combined usage of IVUS and OCT is proven to improve
high-risk plaque detection in multiple studies. Sawada et al.
used both VH-IVUS and OCT to detect TCFA in n= 56
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patients with established angina. In total, 126 lesions were
evaluated, demonstrating that each modality had an adequate
absolute sensitivity and specificity for identifying TCFA,
which improved when combined [79]. Similarly, Gonzalo
et al. demonstrated improved diagnostic precision using VH-
IVUS and OCT [80]. Although single-catheter IVUS-OCT
systems are in development, significant barriers remain.
Hybridisation of VH-IVUS and NIRS Although enabling
characterisation of plaque architecture, IVUS has limited ca-
pability in identifying plaque composition. VH-IVUS analysis
provides more data but is subject to underestimation of lipid
tissue behind calcified plaques and in stent segments.
Brugaletta et al. performed a study comparing VH-IVUS
and NIRS in n=31 patients with angina, demonstrating poor
concordance between the identification of NC on VH-IVUS
and LCP on NIRS, despite good sensitivity and specificity for
the individual techniques, and the prior association of both
entities with adverse events [73]. A study by Pu et al. observed
similar findings [81]. Thus, the fusion of these technologies
may improve detection of vulnerable plaque. The integration
of an ultrasound image to demonstrate morphology, with a
chemogram to identify lipid-rich regions, is theoretically ad-
vantageous, although evidence is limited regarding the incre-
mental diagnostic utility of this technique. It is currently being
used to assess statin-mediated plaque regression in IBIS-3
(Integrated Biomarker and Imaging Study-3) [82].
Other Imaging Techniques
In addition to established imaging modalities, there are many
approaches in active, preclinical and clinical development.We
briefly review some of the more prominent technologies.
Coronary AngioscopyUsing high-resolution (10–50-μm) fi-
bre optics, coronary angioscopy permits the visualisation of
the arterial intima and plaque surface [83]. Although capable
of assessing superficial characteristics (such as colour), iden-
tifying red and white thrombus and detecting localised dam-
age to the vessel wall, (e.g. flaps, fissure, ulceration),
angioscopy provides limited insight into plaque morphology.
Preliminary data suggests that plaque colour, related to fibrous
cap thickness, may be associated with vulnerability (intensely
yellow plaques have thinner fibrous caps, predisposing to rup-
ture) [84]. However, angioscopy requires a bloodless field and
is highly operator dependent, limiting routine application. As
such, coronary angioscopy is primarily limited to research use.
Intravascular MRI The development and application of an
intravascular MRI probe, integrated within the tip of a coronary
catheter and capable of identifying TCFA in intact, post-mortem
coronary arteries, was demonstrated by Schneiderman et al.
[85]. This proof-of-concept device contained both a magnet
and coil within a 1.73 mm diameter. The probe produced axial
images, with penetration of 250 μm, and achieved an estimated
resolution of 100 μm. In preliminary analysis of post-mortem
vessels, intravascular MRI identified vulnerable lesions with a
sensitivity and specificity of 100 and 89 %, respectively.
However, long image acquisition times (2.5–4 min), requiring
occlusion of the artery, have proven a barrier to translating this
technology into in vivo applications.
Raman SpectroscopyRaman spectroscopy identifies organic
molecules, using the Raman shift principle, the inelastic scat-
tering of monochromatic light from a laser source, when it
reflects off a substance. The unique molecular characteristics
of each plaque constituent, particularly lipid and calcium, and
their corresponding Raman shift patterns, enable Raman spec-
troscopy to sensitively detect a coronary plaque [86]. An al-
gorithm, derived from the relative contributions of the inde-
pendent spectra of the constituents of an atherosclerotic
plaque, has been validated [87]. However, intracoronary ap-
plications have numerous limitations, such as the small pro-
portion of photons that become shifted, resulting in a poor
signal-to-noise ratio and limited tissue penetration.
Near-Infrared Fluorescence Molecular Imaging Using
technology similar to NIRS, intravascular near-infrared fluo-
rescence molecular imaging utilises the phenomenon of mo-
lecular fluorescence to identify specific regions of arterial in-
flammation and injury [88]. Near-infrared fluorescence
(NIRF) permits a targeted approach to the identification of
plaque components (e.g. lipid core). Preclinical, proof-of-
concept studies have used NIRF catheters, in conjunction with
a cysteine protease imaging reporter, for in vivo intracoronary
imaging in animal models. Jaffer et al. report high-resolution
spatial mapping of arterial inflammation, superimposed on
IVUS imaging, to identify high-risk plaque regions [89].
A comparison of all imaging technologies described in this
review is presented in Table 1.
Clinical Guidelines
Evidence-based clinical practice guidelines, regarding the usage
of intracoronary imaging, have been developed by the ACC/
AHA/SCAI and ESC/EACTS. The 2011 North American
guidelines recommend the use of IVUS which is reasonable
for the assessment of (i) angiographically indeterminate left
main CAD (class IIa, level of evidence B) and (ii) non-left main
coronary arteries with angiographically intermediate stenoses
(50–70 %; class IIb, level of evidence B) [90]. The guidelines
suggest other situations in which the IVUS may have clinical
utility, such as in the evaluation of the aetiology of stent reste-
nosis (class IIa, level of evidence C) and thrombosis (class IIb,
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level of evidence C). The routine use of IVUS for lesion evalu-
ation, when PCI is otherwise not intended, is not recommended
(class III). Although the guideline acknowledges OCT, it does
not provide recommendations for usage outside of clinical re-
search. No recommendations are made regarding other imaging
modalities. The 2014 European guidelines advocate IVUS in
selected patients (i) to optimise stent placement (class IIa, level
of evidence B) and (ii) to assess severity and optimise treatment
of unprotected left main lesions (class IIa, level of evidence B)
[91]. The guideline also advises consideration of IVUS and/or
OCT to detect stent-related mechanical problems (e.g. resteno-
sis, thrombosis; class IIa, level of evidence C) and OCT in
selected patients to optimise stent implantation (class IIb, level
of evidence C). No recommendations are made regarding other
imaging modalities. Both recommendations advocate the need
for further clinical research to demonstrate that the use of
intracoronary imaging techniques improves clinical outcomes.
Conclusion
The development of invasive intracoronary imaging, exempli-
fied by IVUS, OCT and NIRS, has revolutionised an under-
standing of the pathophysiology of coronary artery disease.
Translation into the cardiac catheterisation lab has permitted
detailed, in vivo identification and evaluation of high-risk,
vulnerable coronary plaques in both clinical research and car-
diology practice. Of the available array of imaging modalities,
each has distinct advantages and disadvantages: VH-IVUS
enables precise characterisation of plaque architecture but
lacks spatial resolution. OCT permits high-resolution mea-
surement of the fibrous cap but has limited penetration
through the arterial wall. NIRS robustly detects lipid cores
but provides limited quantitative data regarding the coronary
lumen or plaque morphology. Hybrid approaches negate these
limitations and are gaining traction in early clinical studies.
Numerous novel imaging technologies are under develop-
ment. However, while improved image quality is imperative,
nascent techniques must add value to existing approaches.
Robust clinical trials are required to evaluate whether invasive
intracoronary imaging improves patient outcomes.
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